CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 33 enrolled
Drug / intervention
Aspirindrug
Likely dose
Aspirin 81 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01894555
NCT01894555Phase 4Completed
CompareCT.gov

Pharmacogenomics of Antiplatelet Response - II

Johns Hopkins University·interventional·Posted Jul 10, 2013·Updated Jan 9, 2017

In Brief

A Phase 4 clinical trial evaluating Aspirin for Atherothrombosis. Completed, enrolled 33 participants across 1 site.

Detailed Summary

This clinical trial is examining the effect of 4-week aspirin therapy on platelet transcriptome in persons at high-risk for myocardial infarction or stroke due to family history of early-onset coronary artery disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtherothrombosis
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJul 10, 2013
Enrollment StartJan 1, 2013
Primary CompletionAug 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 13.0 years ago

Interventions

Aspirindrug

81 mg daily for 4 weeks